SPI 5557
Alternative Names: SPI-5557Latest Information Update: 10 Dec 2024
Price :
$50 *
At a glance
- Originator Sound Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Cyclin-dependent kinase inhibitor p27 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sensorineural hearing loss
Most Recent Events
- 10 Dec 2024 Sound Pharmaceuticals plans to file an IND application for Sensorineural hearing loss (Sound Pharmaceuticals pipeline, December 2024)
- 04 Sep 2024 Preclinical trials in Sensorineural hearing loss in USA (unspecified route) before September 2024 (Sound Pharmaceuticals pipeline, September 2024)